|
caruncle
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to document the expression and functional role of BMPs in the placental (caruncle; CAR, cotyledon; COT) during different stages of pregnancy in water buffalo.
|
31445010 |
2020 |
|
Renal cancer metastatic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
|
31574023 |
2020 |
|
Adenoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Eight- to fifteen-year-old dogs with carcinoma (CAR Group; N=5), epithelioma (EPI Group; N=16) or adenoma (ADE Group; N=24) were used.
|
31028190 |
2019 |
|
Anemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Neutropenia, thrombocytopenia, and anemia occur frequently (94, 80, and 51%, respectively) after CAR-T cell infusion, and are associated with a biphasic nature, as in 93% of patients hematologic toxicity occurs after 21 days from cell infusion.
|
30809033 |
2019 |
|
Blood Coagulation Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.
|
31055613 |
2019 |
|
Bone neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
In this review, we briefly describe the CAR-T approach and discuss its applications in primary bone tumors.
|
31441962 |
2019 |
|
Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated the cytolytic and mechanistic activity of anti-CD19 chimeric antigen receptor natural killer (CD19.CAR.NK92) therapy in lymphoma cell lines (diffuse large B-cell, follicular, and Burkitt lymphoma), including rituximab- and obinutuzumab-resistant cells, patient-derived cells, and a human xenograft model.
|
31772298 |
2019 |
|
Malignant neoplasm of thyroid
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These studies support the initiation of a phase I study to evaluate the safety and potential efficacy of micromolar affinity tuned CAR T cells against newly diagnosed anaplastic and refractory or recurrent thyroid cancers.
|
31337787 |
2019 |
|
Hodgkin Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review focuses on application of CAR-T cells in hematologic malignancies beyond targeting CD19, with specific attention to Hodgkin's lymphoma and acute myeloid leukemia.
|
30632631 |
2019 |
|
Immune System Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets.
|
31186046 |
2019 |
|
Leukemia, Mast-Cell
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here, we report a case of a refractory MCL in a patient who had relapsed after conventional chemotherapy and autologous CAR T cell therapy.
|
30791947 |
2019 |
|
Lymphohistiocytosis, Hemophagocytic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The overwhelming release of cytokines and chemokines by activated CAR-T and other secondarily activated immune effector cells can lead to cytokine release syndrome (CRS), which can have clinical and pathophysiology similarities to systemic inflammatory response syndrome and macrophage activating syndrome/hemophagocytic lymphohistiocytosis.
|
31355491 |
2019 |
|
Lymphoma, Follicular
|
0.010 |
Biomarker
|
disease |
BEFREE |
No significant differences in CAR-T cell in vivo expansion/persistence were observed between FL and tFL patients.
|
31648294 |
2019 |
|
Mesothelioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To explore CAR-T therapy in NSCLC and mesothelioma, second-generation CAR-T cells were constructed targeting mesothelin (MSLN), which is abundant in NSCLC and mesothelioma but is under expressed in normal tissues.
|
30651858 |
2019 |
|
Myocarditis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CAR transcription levels were significantly lower (P=0.012) in patients with myocarditis compared with controls, and a significant decrease was observed (P=0.023) in CAR mRNA levels among patients with borderline myocarditis compared with the no myocarditis group.
|
31257515 |
2019 |
|
Delirium, Dementia, Amnestic, Cognitive Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Neuropsychiatric symptoms are common among older people with neurocognitive disorders in CAR and ROC.
|
30255569 |
2019 |
|
Pancytopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Following lymphodepletion, CAR-T cells targeting the tumor-associated antigen ROR1 lysed tumors in mice but induced lethal bone marrow failure due to recognition of ROR1<sup>+</sup> stromal cells.
|
30889382 |
2019 |
|
Pleural effusion disorder
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Comparing NSCLC PE and published plasma levels of CAR-T recipients, both were dominated by sIL-6Rα and IL-6 but NSCLC PE had more VEGF, FGF2 and TNFα, and less IL-2, IL-4, IL-13, IL-15, MIP1α and IFNγ.
|
31741710 |
2019 |
|
Thyroid Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.
|
31337787 |
2019 |
|
Lymphoma, Large-Cell, Follicular
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lastly, we will describe novel CAR-T constructs currently under exploration in B cell NHL.
|
30652353 |
2019 |
|
Depressive Symptoms
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Two hierarchical logistic regressions, one including the TSST response and one including the CAR as predictor variables, suggest that cortisol reactivity, social support from the baby's father, and neuroticism contribute to depressive symptoms, controlling for GA (both p < .01).
|
30703466 |
2019 |
|
Migraine Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Although non-specific, serum NLR, MLR, PLR, and CAR levels may be potential biomarkers associated with migraine subtypes with different clinical features such as migraine attack period, migraine with aura, and patients with family history of migraine.
|
31758522 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our data suggest that MAGE-A1 is a promising candidate marker for LUAD therapy and the MAGE-A1-specific CAR-T cell immunotherapy may be an effective strategy for the treatment of MAGE-A1-positive LUAD.
|
31640756 |
2019 |
|
Adult Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review focuses on application of CAR-T cells in hematologic malignancies beyond targeting CD19, with specific attention to Hodgkin's lymphoma and acute myeloid leukemia.
|
30632631 |
2019 |
|
Childhood Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review focuses on application of CAR-T cells in hematologic malignancies beyond targeting CD19, with specific attention to Hodgkin's lymphoma and acute myeloid leukemia.
|
30632631 |
2019 |